Literature DB >> 31394499

Dynamic risk assessment in patients with differentiated thyroid cancer.

Fabian Pitoia1, Fernando Jerkovich1.   

Abstract

The stratification of patients with differentiated thyroid cancer based on their initial risk of recurrence, according to specific clinical, histopathological and perioperative data, is an important starting point for tailoring the follow-up during the first 1-2 years after initial therapy (surgery with or without radioiodine ablation). However, risk of recurrence re-stratification based on new clinical data that becomes available after considering the response to treatment (dynamic risk assessment) provides a more accurate prediction of the status at final follow-up and a more individualized approach. In this review, we summarized the available data regarding dynamic risk of recurrence and the suggested management of differentiated thyroid cancer patients according to the response to treatment. The use of this strategy is crucial to avoid overtreatment and intensive follow-up of the vast majority of patients who will have a very good prognosis and, on the other hand, focus therapeutic efforts on those patients who will have a worse prognosis. In the future, molecular biology analysis of the tumors and well-designed prospective studies will probably refine the risk of recurrence prediction.

Entities:  

Keywords:  differentiated thyroid cancer; dynamic risk; risk of recurrence; thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 31394499     DOI: 10.1530/ERC-19-0213

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

Review 1.  Revision Thyroid Surgery.

Authors:  Karthik Nagaraja Rao; Satish Satpute; Nitin M Nagarkar; Ambesh Singh
Journal:  Indian J Surg Oncol       Date:  2021-11-04

2.  Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature.

Authors:  Costanza Chiapponi; Milan J M Hartmann; Matthias Schmidt; Michael Faust; Christiane J Bruns; Anne M Schultheis; Hakan Alakus
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

Review 3.  Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.

Authors:  Likun Cui; Dongdong Feng; Chaofan Zhu; Qiuyu Li; Wenqing Li; Baoguo Liu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-21

4.  Quality of Life of Survivors of Thyroid Cancer Is Not Inferior to That in Subjects without Cancer: Long-Term after Over 5 Years.

Authors:  Jeongmin Lee; Youn-Ju Lee; Dong-Jun Lim; Jung-Min Lee; Sang-Ah Chang; Min-Hee Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-08-29

5.  Natural Course of the American Thyroid Association Response to Therapy Statuses (Dynamic Risk Stratification) in Differentiated Thyroid Cancer.

Authors:  Noha Mukhtar; Hadeel Aljamei; Abeer Aljomaiah; Yosra Moria; Ali S Alzahrani
Journal:  Eur Thyroid J       Date:  2020-12-01

6.  Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer.

Authors:  Ali S Alzahrani; Yosra Moria; Noha Mukhtar; Hadeel Aljamei; Sedra Mazi; Lina Albalawi; Abeer Aljomaiah
Journal:  J Endocr Soc       Date:  2020-11-11

Review 7.  Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers.

Authors:  Maria Trovato
Journal:  Diagnostics (Basel)       Date:  2022-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.